Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
7.51
-0.15 (-1.96%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :11,777
Date :04-25-2018
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin

April 23rd, 2018|

90-day dosing study is a prerequisite to Phase 3 confirmatory studies under FDA’s BLA

NEW YORK, April 23, 2018 /PRNewswire/ —  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development […]

Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference

March 27th, 2018|

NEW YORK, March 27, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting […]

Oramed to Present at Oppenheimer’s Annual Healthcare Conference

March 15th, 2018|

NEW YORK, March 15, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming […]

Oramed Adds Two New Members to its Scientific Advisory Board

February 28th, 2018|

NEW YORK, Feb. 28, 2018  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert […]